Literature DB >> 26891910

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Takeshi Yamada1, Yoshiyuki Yamamoto2, Toshikazu Moriwaki2, Ichisnosuke Hyodo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26891910     DOI： 10.1007/s00535-016-1184-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  3 in total

1.  Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer?

Authors:  Ichinosuke Hyodo
Journal:  Gastric Cancer       Date:  2012-04       Impact factor: 7.370

2.  Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.

Authors:  Jun Zhou; Zhi Peng; Yi Liu; Jifang Gong; Xiaotian Zhang; Ming Lu; Jing Gao; Yili Li; Yanyan Li; Lin Shen
Journal:  J Gastroenterol       Date:  2015-02-22       Impact factor: 7.527

Review 3.  Challenges in the clinical utility of the serum test for HER2 ECD.

Authors:  Lian Lam; Nicholas McAndrew; Marla Yee; Ting Fu; Julia C Tchou; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2012-04-03
  3 in total
  2 in total

1.  Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).

Authors:  Yuji Miura; Yasutaka Sukawa; Shuichi Hironaka; Misuzu Mori; Kazuhiro Nishikawa; Shinya Tokunaga; Hiroyuki Okuda; Takeshi Sakamoto; Keisei Taku; Kazuo Nishikawa; Toshikazu Moriwaki; Yuji Negoro; Yutaka Kimura; Keita Uchino; Katsunori Shinozaki; Hiroharu Shinozaki; Nobuyuki Musha; Hirotsugu Yoshiyama; Takashi Tsuda; Yoshinori Miyata; Naotoshi Sugimoto; Tsuyoshi Shirakawa; Miki Ito; Kimio Yonesaka; Kenichi Yoshimura; Narikazu Boku; Katsuhiko Nosho; Toshimi Takano; Ichinosuke Hyodo
Journal:  Gastric Cancer       Date:  2017-05-11       Impact factor: 7.370

2.  Linc00483 as ceRNA regulates proliferation and apoptosis through activating MAPKs in gastric cancer.

Authors:  Defeng Li; Meifeng Yang; Aijun Liao; Bing Zeng; Diqun Liu; Yuhong Yao; Guangsheng Hu; Xuanmin Chen; Zhiqiang Feng; Yanlei Du; Youlian Zhou; Jie He; Yuqiang Nie
Journal:  J Cell Mol Med       Date:  2018-05-15       Impact factor: 5.295
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.